新生儿和儿科重症病房护理
1Emergency/Critical Care, Department of Medical Sciences, University of Wisconsin - Madison, Madison, WI 53706, USA.
The Veterinary clinics of North America. Small animal practice
|September 19, 2025
概括
这篇文章适应了"20的规则"对于重症新生儿和儿科患者. 它为这些独特的患者群体创建结构化治疗计划提供了特殊考虑.
科学领域:
- 儿科重症监护医药 儿科重症监护医药
- 新生儿生理学 新生儿生理学
- 临床治疗方案的临床治疗方案.
背景情况:
- 新生儿和儿科患者具有独特且快速变化的生理学.
- 重症儿童需要专门的,结构化的治疗计划.
- 现有的治疗指南可能无法完全满足儿科患者群体的特定需求.
研究的目的:
- 为了调整已建立的.
- 在住院的新生儿和儿科患者中应用的20"规则参数.
- 概述为为重症新生儿和儿童制定综合治疗计划的特殊考虑因素.
- 为管理儿科重症监护提供一个结构化的方法.
主要方法:
- 审查和调整现有的"20项规则"临床参数.
- 对新生儿和儿科患者群体生理差异的分析.
- 在儿科重症监护中制定治疗规划的具体指南.
主要成果:
- "20的规则"可以有效地适应指导重症新生儿和儿童的治疗计划.
- "20的规则"的具体修改解决了儿科患者独特的生理状态.
- 结构化方法提高了治疗计划的彻底性和完整性.
结论:
- 适应"20的规则"为儿科重症监护提供了一个有价值的框架.
- 专业考虑对于优化新生儿和儿科患者的治疗至关重要.
- 这种适应的方法支持基于证据和个性化的患者护理.
更多相关视频
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Pharmacokinetics in Pediatric Patients: Drug Metabolism
195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195


